PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Therapeutic Use
- 12 Dec 2018 Status changed from not yet recruiting to recruiting.
- 09 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.
- 31 Aug 2018 Biomarkers information updated